Niemann-Pick diseases are acquired through autosomal recessive inheritance, which means that the affected individual inherits two faulty (mutated) genes, one from each parent. If an individual has a single copy of the mutated gene, they are known as a carrier, and it will have no noticeable effect on their everyday lives and health.
The child may inherit identical mutations from each parent (referred to as homozygous), which can sometimes arise through intermarriage, although this may not be obvious over many generations. In other instances the parental mutations may be different and is referred to as heterozygous.
In every pregnancy of a couple who each carry a copy of the faulty Niemann-Pick gene:
Genetic testing (or screening) is a type of medical test that aims to identify changes in chromosomes, genes or proteins. The results of these tests can confirm or rule out a suspected genetic condition (such as Niemann-Pick disease), or help determine a person’s chance of developing or passing on a genetic disorder.
Genetic testing usually involves having a small sample of your blood or tissue taken, as this sample will contain cells which hold your DNA. Your blood can then be tested to find out whether you are carrying a particular mutation, and are consequently at risk of developing a particular genetic condition. More than 1,000 genetic tests are currently used, and more are being developed each year.
Genetic counselling is a service that provides support, information and advice about genetic conditions. It is conducted by specialist healthcare professionals who have been trained in genetics. Genetic counselling can:
Genetic counselling is recommended for all couples in which both partners are known to be carriers, or if one partner is a known carrier and the other’s status is uncertain.
Prenatal diagnosis for Niemann-Pick disease is possible. If the DNA mutations of both parents are known, then the process of prenatal diagnosis can be much quicker.
The following tests may be conducted for prenatal diagnosis:
Carrier testing is conducted to determine if a person is a carrier for a specific autosomal recessive disease, such as Niemann-Pick disease. This kind of testing is primarily used by couples who are considering becoming pregnant to determine the risks of their child inheriting a genetic disorder.
Carrier testing is usually only possible once there is an affected person in the family and following the identification of the gene mutation(s). In Niemann-Pick Disease Type C (NP-C), molecular genetic analysis may be used for carrier testing if the specific mutations have been identified in the family. The known mutations of the Niemann-Pick Disease Type A (NP-A) and Niemann-Pick Disease Type B (NP-B) have been well-studied and DNA testing is available; some ethnic groups, including Ashkenazi Jews, North Africans, Arabs and Turks, may have higher frequencies of these conditions.
For the general population, carrier testing for Niemann-Pick disease is not yet available.
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.Read more
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).Read more